[
  {
    "question": "What is true about JME.",
    "option_a": "Can be provoked by photic stimulation",
    "option_b": "Most patients will be seizure free",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Juvenile Myoclonic Epilepsy (JME) is a common idiopathic generalized epilepsy that typically begins in adolescence. It is characterized by myoclonic jerks often occurring shortly after awakening, with the possibility of generalized tonic-clonic seizures and sometimes even absence seizures. JME is believed to involve genetic predisposition affecting thalamocortical circuits and ion channels. A significant proportion of patients with JME exhibit photosensitivity, wherein exposure to flickering lights or certain visual patterns triggers abnormal cortical excitability and subsequent seizures. Clinically, patients with JME may notice that flickering lights (for example, from sunlight through trees, strobe lights, or screens) can provoke seizures. This photosensitivity is one of the hallmarks of JME and is often elicited during EEG testing with photic stimulation. Diagnosis is made through a combination of clinical history, typical age of onset, and EEG findings (often showing polyspike-wave complexes). Differential diagnoses include other generalized epilepsies; however, the pattern of myoclonic jerks, generalized tonic-clonic seizures, and photosensitivity are key features supportive of JME. First-line treatment for JME is typically valproic acid, which is highly effective; however, in women of childbearing age, alternatives such as levetiracetam or lamotrigine are often preferred due to valproate\u2019s teratogenicity. Beyond medication, patients should be advised to avoid triggers such as sleep deprivation and photic stimulation. During pregnancy or lactation, medication choices need to be individualized, balancing seizure control with potential fetal risks. Option A (Can be provoked by photic stimulation) is correct because photosensitivity is a well-recognized trigger in JME. Option B (Most patients will be seizure free) is misleading; while many patients attain good control with appropriate therapy, JME typically requires lifelong treatment and constant vigilance against triggers. Options C and D are not provided, making A the clearly correct statement. 1. Nearly one-third to one-half of JME patients exhibit photosensitivity on EEG, making photic stimulation a valuable diagnostic tool. 2. JME is best managed with a careful balance of seizure control and trigger avoidance. 3. Medication choice in JME needs extra caution in women of childbearing potential due to teratogenic risks. Recent updates in epilepsy management underscore that JME remains a syndrome with excellent response to treatment when appropriately managed. Current research emphasizes the importance of tailored antiseizure medication choices, especially regarding pregnancy and lactation, and underlines photic sensitivity as a pivotal clinical and diagnostic feature.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient has MTLE on 2 sufficient anti seizure medications, but still has monthly seizures next.",
    "option_a": "Start workup for epilepsy Surgery",
    "option_b": "Add 3rd ASMs",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Drug\u2010resistant epilepsy is defined as the failure of at least two appropriately chosen and adequately dosed anti-seizure medication (ASM) regimens to achieve sustained seizure freedom. In patients with mesial temporal lobe epilepsy (MTLE) who continue to have seizures, it becomes essential to consider alternative treatment strategies. In MTLE, structural abnormalities such as hippocampal sclerosis may be the underlying cause, leading to an epileptogenic focus that is less responsive to medications. Continued seizures despite two adequate ASM trials suggest that the epileptic network may be refractory to pharmacological modulation, making surgical resection a viable option. A patient with MTLE who continues to have monthly seizures on two sufficient ASMs meets the criteria for drug-resistant epilepsy. This refractoriness is clinically important because continued seizures significantly affect quality of life and increase risks such as cognitive decline and injury. Before proceeding with surgery, a thorough evaluation is needed which includes long-term video EEG monitoring, high-resolution MRI to localize structural lesions, and possibly functional imaging (PET, SPECT) to better delineate the epileptogenic zone. Differential diagnoses include poorly defined seizure types related to multifocal or generalized epilepsy and medication non-compliance. According to current guidelines, if a patient with focal epilepsy (such as MTLE) fails to achieve seizure freedom with two adequate ASM trials, a surgical evaluation is recommended. First-line management for drug-resistant MTLE is to perform a comprehensive presurgical workup. If the patient is found to be a suitable candidate, surgical resection (often anterior temporal lobectomy) is pursued. For patients who are not surgical candidates, palliative options or neurostimulation devices may be considered. In women of childbearing age or in pregnancy/lactation, the risks and benefits of surgery and medication adjustments should be carefully discussed, as uncontrolled seizures can also pose substantial risks. Option A (Start workup for epilepsy Surgery) is correct because guidelines support early surgical evaluation in drug-resistant MTLE. Option B (Add 3rd ASMs) is not advised as evidence indicates that adding more medications after two adequate trials often results in increased side effects without significant improvement in seizure control. 1. Failure of two adequate ASM trials defines drug-resistant epilepsy. 2. MTLE with hippocampal sclerosis is a common candidate for epilepsy surgery. 3. Early surgical intervention can significantly improve quality of life in refractory cases. Recent research reinforces the benefits of early surgical evaluation for MTLE patients, showing that timely intervention can lead to better seizure control and improved cognitive and quality-of-life outcomes. Multicenter studies and updated guidelines continue to advocate for a surgical workup after two ASM failures.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Female young Epileptic patient on topamax has decreased concentration what to switch to?",
    "option_a": "Lamotrigine",
    "option_b": "Phenytoin",
    "option_c": "Lacosamide",
    "option_d": "zosimide",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "When a patient experiences adverse cognitive effects from an anti-seizure medication, it is important to adjust the treatment regimen to maintain seizure control while minimizing side effects. Topiramate, while effective, is known for its cognitive side effects. Topiramate has multiple mechanisms of action including inhibition of voltage-dependent sodium channels and enhancement of GABA activity, but also inhibits carbonic anhydrase. These effects can impair cognitive functions such as concentration and memory. Lamotrigine, on the other hand, acts primarily through inhibition of voltage-sensitive sodium channels and has a relatively benign cognitive side-effect profile. In young female patients with epilepsy, cognitive function is critical not only for daily performance but also for long-term educational and occupational outcomes. The cognitive blunting often seen with topiramate can significantly affect quality of life, making it reasonable to switch to a medication with fewer adverse cognitive effects. A detailed history focusing on timing and severity of cognitive changes, along with assessment of seizure control and other side effects, guides the decision to adjust therapy. Differential considerations include evaluating other causes of decreased concentration such as sleep disorders, mood disorders, or other metabolic imbalances. First-line management when cognitive side effects are problematic is to consider switching from topiramate to another ASM with a more favorable cognitive profile. Lamotrigine is a well-established alternative with effectiveness in various seizure types and an overall benign side effect profile. In women of childbearing age, lamotrigine is especially favorable given its comparatively low teratogenic risk. However, women should be monitored during pregnancy as lamotrigine clearance increases, necessitating dose adjustments. Option A (Lamotrigine) is correct because it offers effective seizure control with fewer cognitive side effects. Option B (Phenytoin) has its own cognitive and systemic toxicity issues. Option C (Lacosamide) is less commonly used as a first-line alternative for cognitive issues. Option D (zosimide) is not a standard or well-recognized anti-seizure medication in this context. 1. Topiramate is frequently associated with cognitive impairment (eg, word-finding difficulties, decreased concentration). 2. Lamotrigine is preferred in young women due to its favorable safety profile and lower cognitive impact. 3. Monitor lamotrigine levels during pregnancy due to increased metabolism. Recent guidelines and studies emphasize the importance of minimizing cognitive side effects. Lamotrigine has emerged as a preferred alternative in such scenarios, with evidence supporting its use in women where cognitive performance and pregnancy safety are key considerations.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly known case of DM, HTN, hyperlipidemia, Osteoporosis, came with seizure management",
    "option_a": "Valproate",
    "option_b": "phenytoin",
    "option_c": "Lamotrigine",
    "option_d": "Lacosamide",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Choosing an appropriate ASM in elderly patients with multiple comorbidities requires balancing efficacy with the risk of adverse effects and drug interactions. This is especially important in patients with conditions like diabetes, hypertension, hyperlipidemia, and osteoporosis. Elderly patients often have altered pharmacokinetics, including reduced renal and hepatic clearance. ASMs like phenytoin can interact with multiple medications and exacerbate conditions like osteoporosis due to enzyme induction. Lamotrigine, with its more favorable pharmacokinetic profile and lower interaction potential, minimizes additional burden on compromised physiological systems. In an elderly patient with multiple systemic comorbidities, the risk of adverse effects from enzyme-inducing ASMs or those with significant metabolic or bone health impacts is high. Lamotrigine is therefore a prudent choice, offering effectiveness in managing seizures, particularly focal seizures, with a lower risk of aggravating existing conditions. The evaluation involves confirming seizure type (often focal in the elderly), assessing the overall comorbidity burden, and reviewing the full medication list to avoid drug-drug interactions. Differentiating seizure management in the elderly includes considering alternatives like levetiracetam versus lamotrigine, with attention to mood and cognitive effects. For elderly patients, first-line therapy often includes ASMs with fewer cognitive and systemic side effects. Lamotrigine is recommended as it has a low interaction profile. Dose titration should be done slowly due to increased sensitivity in the elderly. Pregnancy and lactation are less common concerns in this age group; however, if encountered, lamotrigine remains one of the safer options. Option A (Valproate) is less appropriate in the elderly due to potential weight gain, tremor, and bone health issues. Option B (Phenytoin) poses risks of more drug interactions and osteoporosis exacerbation. Option C (Lamotrigine) is correct due to its favorable side effect profile. Option D (Lacosamide) is an emerging option but not as well established in the elderly compared to lamotrigine. 1. In elderly patients, the risk of drug interactions and exacerbation of comorbidities is a major concern. 2. Lamotrigine offers a favorable safety profile and is often well-tolerated in older individuals. 3. Slow dose titration is important in the elderly to minimize side effects. Recent studies and guidelines continue to support the use of lamotrigine (and also levetiracetam) as first-line options for focal seizures in the elderly, emphasizing the importance of a medication profile with minimal negative interactions and systemic side effects.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Which of these is a characteristic of LGS.",
    "option_a": "Resistant to antiepileptic medications.",
    "option_b": "Peak onset 5-10 years.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Lennox-Gastaut Syndrome (LGS) is a severe form of childhood-onset epileptic encephalopathy characterized by multiple, often refractory, seizure types, and cognitive dysfunction. LGS involves a complex epileptogenic process with diffuse and multifocal brain dysfunction. The hallmark EEG findings include slow spike-wave complexes. Its refractoriness is due to the underlying widespread brain involvement and the multifactorial nature of the seizures. Clinically, LGS is known for its resistant seizures that are difficult to control and a generally poor response to standard antiepileptic drugs. Patients often present with multiple types of seizures including tonic, atonic, and atypical absence seizures, along with developmental delays and cognitive impairment. Diagnosis is based on clinical features and characteristic EEG findings. Differential diagnoses include other epileptic encephalopathies such as Dravet syndrome or West syndrome. The age of onset is usually in early childhood with a typical presentation that includes multiple seizure types and developmental issues. Management of LGS is challenging. First-line treatment options include valproate, lamotrigine, and topiramate. Second-line options often include clobazam, rufinamide, and the ketogenic diet. Given the refractory nature, polytherapy is common. Although most management guidelines focus on pediatric patients, considerations in adolescence or women of childbearing age require balancing seizure control with long-term cognitive and developmental outcomes, and certain medications have teratogenic risks. Option A (Resistant to antiepileptic medications) is correct because one of the defining characteristics of LGS is its refractoriness to standard therapies. Option B (Peak onset 5-10 years) is incorrect since the typical onset of LGS is usually in early childhood (commonly between 3 and 5 years, although the age range can vary). 1. LGS is a prototypical drug-resistant epileptic encephalopathy. 2. It involves multiple seizure types and is often accompanied by significant cognitive impairment. 3. Early aggressive management, including dietary and combination therapies, is often required despite limited seizure control. Recent research continues to underscore the refractory nature of LGS. Advances in therapy, including newer ASMs and non-pharmacologic approaches such as the ketogenic diet and neurostimulation, are areas of active investigation, although no curative treatment currently exists.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Boy with seizure, uncontrolled, he is known case of bipolar, management:",
    "option_a": "Carbamazepine",
    "option_b": "Levetiracetam",
    "option_c": "Valproate",
    "option_d": "Lamotrigine",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "In patients with comorbid epilepsy and bipolar disorder, using an agent that serves dual purposes is ideal. Valproate is an antiepileptic that is also effective as a mood stabilizer, making it a preferred choice in cases where seizures coexist with bipolar disorder. Seizures result from abnormal, synchronous neuronal discharges, while bipolar disorder involves dysregulation of mood and affect. Valproate increases gamma\u2010aminobutyric acid (GABA) levels and modulates sodium channels, thereby reducing neuronal excitability. Its mood\u2010stabilizing properties help reduce the frequency and intensity of mood swings by influencing brain neurotransmitter systems. A boy with uncontrolled seizures who also has a diagnosis of bipolar disorder benefits from valproate because it can address both the seizure activity and mood instability. This dual action can simplify management and possibly improve overall outcomes. When confronted with a patient whose seizure control is suboptimal, it\u2019s important to re\u2010evaluate the seizure type, consider medication levels, and review comorbidities. Differential diagnoses might include focal versus generalized seizures and drug interactions. In this case, a careful history and possibly EEG studies help in confirming the seizure type before choosing a therapy that also covers the psychiatric indication. According to current guidelines, valproate is considered first-line for generalized seizures and is highly effective in controlling a variety of seizure types. For patients with bipolar disorder, valproate is frequently used as a mood stabilizer. Although valproate is contraindicated in pregnancy due to its teratogenicity, this is not a concern in a pediatric male. In adults who are or may become pregnant, alternative agents (such as lamotrigine, which has a better teratogenic profile) might be preferred. A: Carbamazepine \u2013 While it is an antiepileptic and sometimes used in mood disorders, it is not as effective on both fronts as valproate. B: Levetiracetam \u2013 An effective antiepileptic, but it lacks the mood-stabilizing benefit. D: Lamotrigine \u2013 More effective for bipolar depression and maintenance therapy but may not adequately control uncontrolled seizures in this context. 1. Valproate is a first-line treatment in generalized seizures and is a preferred mood stabilizer in patients with bipolar disorder. 2. Dual efficacy in controlling seizures and mood swings can simplify the medication regimen. 3. Monitor for side effects such as hepatotoxicity and weight gain, particularly with long-term use. Recent clinical guidelines continue to support the use of valproate for patients with generalized seizures and coexisting bipolar disorder. Research underscores the importance of selecting an agent that treats both conditions, especially when treatment adherence may be influenced by polypharmacy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Old lady with DM, HTN, Afib had an episode of syncope followed by convulsions. The episode was witnessed by the family and they reported that the patient was confused for a short period after it. Upon presentation to ED her BP was 90/70, she was fatigued but conscious and oriented. WOTF help you with the diagnosis?",
    "option_a": "Rhythmic clonus",
    "option_b": "Multifocal myoclonus",
    "option_c": "Oral automatism",
    "option_d": "Up rolling of eyes",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Distinguishing between epileptic seizures and convulsive syncope is crucial. Convulsive syncope is characterized by transient global cerebral hypoperfusion leading to brief, non-epileptic motor phenomena, often with myoclonic jerks that may appear multifocal rather than the rhythmic clonus seen in true seizures. In syncope, the drop in cerebral blood flow (often due to cardiovascular causes like hypotension) causes transient neuronal dysfunction. This can manifest as brief convulsive movements. The multifocal myoclonus seen is usually irregular and reflects the brain\u2019s global response to hypoperfusion rather than the organized, rhythmic discharges of epilepsy. The patient, an elderly lady with diabetes, hypertension, and atrial fibrillation, experienced syncope with subsequent convulsive activity. Her low blood pressure on arrival and the short period of confusion suggest a transient cerebral ischemia rather than a prolonged postictal state that is typical of epileptic seizures. Differentiating convulsive syncope from seizures involves a detailed history, eyewitness accounts, and evaluation of cardiovascular status. Differential diagnoses include epileptic seizures, transient ischemic attacks, and orthostatic hypotension. In this case, the presence of multifocal myoclonus, short duration of confusion, and cardiovascular instability point toward convulsive syncope. Management focuses on addressing the underlying cardiovascular issue (e.g., optimizing blood pressure, cardiac rhythm monitoring). Epileptic seizures would be treated with antiepileptic drugs; conversely, in syncope, treatment is supportive and directed at the cause. In pregnant or lactating patients, careful evaluation of blood pressure and avoidance of unnecessary anticonvulsants is important, as many epilepsy drugs carry teratogenic risk. A: Rhythmic clonus \u2013 This is more typical of a true generalized tonic\u2013clonic seizure. C: Oral automatism \u2013 Often seen in temporal lobe epilepsy (complex partial seizures). D: Up rolling of eyes \u2013 Can be seen in epileptic seizures (especially absence seizures or certain focal seizures) but is less specific. B: Multifocal myoclonus \u2013 Reflects irregular, non-rhythmic jerks that are more characteristic of convulsive syncope. 1. Always consider a cardiovascular cause in older patients presenting with syncope and convulsive movements. 2. Multifocal, irregular myoclonic jerks favor a diagnosis of convulsive syncope over rhythmic clonic activity in epilepsy. 3. A brief post-event confusion period is more suggestive of syncope. Recent studies emphasize the importance of differentiating convulsive syncope from seizures through detailed clinical assessment and cardiovascular evaluation. Guidelines encourage clinicians to look at the overall clinical scenario, including witness descriptions and vital signs, to avoid misdiagnosis and unnecessary antiepileptic therapy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with figure of 4, fencing, right side nose rubbing, localization.",
    "option_a": "Lt temporal",
    "option_b": "Rt Temporal",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Certain motor automatisms and posturing observed during seizures are highly localizing. Temporal lobe seizures are known to produce complex automatisms (such as nose rubbing), which often occur ipsilaterally to the seizure focus. The presence of a \u2018fencer\u2019s posture\u2019 or figure\u2010of\u20104 type movement can also be seen as a lateralizing sign in focal seizures. Ictal automatisms in temporal lobe epilepsy result from abnormal discharges in limbic and temporal structures. These discharges can produce repetitive, non-purposeful motor actions (e.g., nose rubbing) and stereotyped postures. The \u2018fencing\u2019 posture is thought to involve abnormal activation of motor pathways which may, in combination with facio-limbic automatisms, help localize the seizure onset. In patients with focal seizures originating from the temporal lobe, automatisms such as ipsilateral nose rubbing are common. When combined with atypical posturing (for example, a figure-of-4 or fencer\u2019s posture), these signs provide useful clues to lateralization. Since the automation is on the right side, it suggests that the seizure focus is in the right temporal lobe. The differential diagnosis for focal seizures includes frontal lobe epilepsy, which may present with different types of motor behaviors. Distinguishing factors include the type of automatisms (complex, repetitive gestures like nose rubbing point to the temporal lobe) versus more bizarre, often brief motor phenomena seen in frontal seizures. EEG and neuroimaging (MRI) further help in localizing the focus. Temporal lobe epilepsy is generally managed with first-line antiepileptic medications such as carbamazepine, lamotrigine, or possibly levetiracetam. In women of childbearing potential or during pregnancy/lactation, lamotrigine is often preferred due to its favorable teratogenic profile compared to other agents. Surgical evaluation is also considered in refractory cases. A: Lt Temporal \u2013 Incorrect because the ipsilateral (right-sided) nasal automatism suggests the focus is on the same side. Options C and D are not provided. B: Rt Temporal \u2013 Correct given the presence of right-sided nose rubbing and associated automatisms, which localize the seizure focus to the right temporal lobe. 1. Ipsilateral facial automatisms like nose rubbing are classic localizing signs in temporal lobe epilepsy. 2. A fencer\u2019s posture can be an important clue to lateralization during seizures. 3. Always correlate clinical findings with EEG and imaging for accurate localization. Recent literature affirms the utility of ictal semiology for seizure localization. Advances in video-EEG monitoring and high-resolution MRI have improved the accuracy of localizing temporal lobe epilepsy, aiding in optimal medical and surgical management strategies.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "3-Hz spike EEG Characterstic of.",
    "option_a": "Absance Seizure",
    "option_b": "West Syndrome",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The EEG pattern known as a 3-Hz spike-wave discharge is pathognomonic for typical absence seizures. These discharges are brief, generalized, and highly synchronized, often correlating with the clinical picture of brief lapses in awareness. Absence seizures arise from abnormal oscillatory activity within the thalamocortical network. The 3-Hz spike-wave pattern reflects disturbances in this network where rhythmic inhibitory and excitatory signals become synchronized abnormally, leading to the transient impairment of consciousness. Patients with typical absence seizures (commonly children) experience brief staring spells with sudden onset and termination, often without postictal confusion. The 3-Hz spike-wave pattern on EEG is an essential diagnostic hallmark that correlates with the clinical episodes. The primary differential diagnosis is between typical absence seizures and other non-convulsive states like complex partial seizures. A characteristic EEG with a regular 3-Hz spike-wave discharge seen during the episode helps confirm the diagnosis of absence seizures. Other forms of generalized epilepsy (e.g., juvenile myoclonic epilepsy) have different EEG features. First-line treatment for absence seizures includes ethosuximide, particularly in children with uncomplicated absence epilepsy. Valproate is an alternative, especially if there is a concurrent generalized tonic-clonic seizure component. In pregnancy or lactation, lamotrigine is sometimes preferred due to a better safety profile, although treatment decisions in these populations require cautious benefit-risk assessment. A: Absence Seizure \u2013 Correct, as the 3-Hz spike-wave pattern is widely recognized as the hallmark of typical absence seizures. B: West Syndrome \u2013 Incorrect, because West Syndrome is associated with a chaotic hypsarrhythmia pattern on EEG, not a regular 3-Hz spike-wave pattern. 1. The classic 3-Hz spike-wave discharge on EEG is nearly diagnostic of absence seizures. 2. Absence seizures are brief, with impaired awareness and rapid recovery without prolonged postictal confusion. 3. Ethosuximide is considered first-line therapy for children with absence epilepsy. Contemporary guidelines and research confirm the 3-Hz spike-wave pattern as characteristic for typical absence seizures. Updated clinical guidelines emphasize the use of ethosuximide as first-line treatment and highlight the importance of EEG in differentiating absence seizures from other forms of epilepsy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "EEG of slow spike characteristic of",
    "option_a": "Lennox",
    "option_b": "West",
    "option_c": "JME",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Electroencephalography (EEG) is an essential tool in diagnosing epileptic syndromes. Certain syndromes produce characteristic patterns on EEG. In this case, a 'slow spike\u2010and\u2010wave' pattern (typically around 1.5\u20132.5 Hz) is classically seen in Lennox\u2013Gastaut syndrome. Lennox\u2013Gastaut syndrome is a severe childhood epileptic encephalopathy characterized by multiple seizure types and cognitive impairment. The slow frequency spike\u2010and\u2010wave discharges reflect widespread cortical dysfunction along with an abnormal thalamocortical circuitry. Structural brain abnormalities or previous brain injuries can contribute to this dysfunctional network. Patients with Lennox\u2013Gastaut syndrome often present with mixed seizure types including tonic, atonic, and atypical absence seizures. The characteristic slow spike\u2010and\u2010wave pattern on EEG helps distinguish it from other pediatric epilepsies such as childhood absence epilepsy (3 Hz spike\u2010and\u2010wave) or juvenile myoclonic epilepsy (polyspike\u2010and\u2010wave complexes). Differential diagnoses include: (1) Childhood absence epilepsy \u2013 typically shows a 3 Hz spike\u2010and\u2010wave pattern, (2) West syndrome \u2013 characterized by a chaotic EEG pattern called hypsarrhythmia, and (3) Juvenile myoclonic epilepsy \u2013 which has faster, polyspike\u2010and\u2010wave discharges. The slow spike\u2010and\u2010wave frequency in Lennox\u2013Gastaut (often <3 Hz) is diagnostic when coupled with the clinical picture. Management is challenging and involves multimodal therapy. First\u2010line treatments include antiepileptic drugs such as valproate, lamotrigine, and topiramate. For refractory cases, adjunctive therapies like the ketogenic diet, vagus nerve stimulation (VNS), or corpus callosotomy may be considered. In pregnancy, teratogenic risks must be carefully weighed; drugs like valproate are contraindicated, and alternative agents such as lamotrigine (with careful monitoring) are preferred. Lactation considerations include minimizing drug exposure in the infant while maintaining maternal seizure control. Option A is correct because Lennox\u2013Gastaut syndrome is known for its slow spike\u2010and\u2010wave EEG pattern. Option B (West syndrome) typically shows a hypsarrhythmic pattern, and Option C (Juvenile Myoclonic Epilepsy) is characterized by fast polyspike\u2010and\u2010wave discharges. \u2022 A slow spike\u2010and\u2010wave frequency (<3 Hz) on EEG is a hallmark of Lennox\u2013Gastaut syndrome. \u2022 Multiple seizure types in combination with cognitive impairment should raise suspicion for this syndrome. \u2022 Early recognition is critical as the syndrome is often drug-resistant and may require non-pharmacologic interventions. Recent guidelines emphasize early and aggressive treatment of Lennox\u2013Gastaut syndrome. There is growing evidence supporting the ketogenic diet and newer agents in reducing seizure frequency along with improvements in quality of life. Multidisciplinary care is recommended to address both seizures and cognitive outcomes.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has partial seizure, PET showed hypometabolism perysilvin.",
    "option_a": "GluR3",
    "option_b": "GLUT-1",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Positron emission tomography (PET) is frequently used in the presurgical evaluation of epilepsy to detect areas of hypometabolism, which may correlate with the epileptogenic zone. In focal epilepsies, a localized area of reduced metabolism helps guide diagnostic and therapeutic decisions. In some patients with partial seizures, particularly those involving the perisylvian region, abnormal receptor activity may contribute to neuronal hyperexcitability. The GluR3 subunit is a component of the AMPA receptor. Abnormalities or autoimmune reactions involving GluR3 have been implicated in some forms of epilepsy, potentially leading to focal dysfunction and seizure activity. Partial (focal) seizures associated with hypometabolism on PET suggest a localized region of dysfunction. When this is coupled with specific receptor abnormalities such as those involving GluR3, it supports the hypothesis of a receptor-mediated epileptogenic process. The main differentials include focal cortical dysplasia, hippocampal sclerosis, and autoimmune epilepsies. GLUT-1 deficiency (Option B) is usually associated with a global disturbance in glucose transport, presenting with a more diffuse pattern of hypometabolism and a broader spectrum of seizure types. Evaluation typically includes a detailed clinical history, neuroimaging, and sometimes analysis of autoantibodies. Management includes first-line antiepileptic drugs (AEDs) aimed at controlling focal seizures, such as carbamazepine, levetiracetam, or lamotrigine. In suspected autoimmune cases, immunomodulatory therapies may be considered. In pregnancy, AED selection must consider teratogenic risks (e.g., minimizing the use of valproate) and drugs such as lamotrigine or levetiracetam are preferred. Lactation considerations involve selecting medications with lower transfer into breast milk and careful monitoring of the infant. Option A (GluR3) is correct because abnormalities in this AMPA receptor subunit have been implicated in focal epileptogenesis, consistent with the PET findings of localized hypometabolism. Option B (GLUT-1) is generally linked to a diffuse metabolic disorder with a different clinical presentation. The other options are not applicable based on the information provided. \u2022 PET hypometabolism can be a reliable marker for localizing epileptogenic foci in partial seizures. \u2022 Abnormalities in glutamate receptors, such as GluR3, can contribute to neuronal hyperexcitability and focal epilepsy. \u2022 Differentiating focal receptor-mediated epilepsies from metabolic disorders (like GLUT-1 deficiency) is crucial for proper management. Recent studies on autoimmune epilepsies have highlighted the role of receptor antibodies, including anti-GluR3, in the pathogenesis of focal epilepsies. However, this area remains evolving, and further research is needed to establish standardized diagnostic and treatment protocols.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with abdominal rising sensation, deja vu, Pathophysiology.",
    "option_a": "Activation dentate nuclear",
    "option_b": "Schaffer collateral from c3 to c1",
    "option_c": "mousse fiber Sth\u2026",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "The aura described \u2013 an abdominal rising sensation combined with d\u00e9j\u00e0 vu \u2013 is a classic presentation of mesial temporal lobe epilepsy, where abnormal activity in the hippocampal formation produces these symptoms. Understanding the hippocampal circuitry is essential to grasp the underlying epileptogenic mechanisms. In mesial temporal lobe epilepsy, one of the hallmark findings in histopathologic studies is 'mossy fiber sprouting.' Mossy fibers, which originate from the granule cells of the dentate gyrus and normally project to the CA3 region, undergo aberrant sprouting. This sprouting creates recurrent excitatory circuits, contributing to hyperexcitability and seizure propagation. Although the Schaffer collaterals (which run from CA3 to CA1) are important in normal hippocampal transmission, they are not the primary culprits in the pathological reorganization seen in temporal lobe epilepsy. Patients with mesial temporal lobe epilepsy frequently complain of epigastric auras (an 'abdominal rising' sensation) and deja vu episodes. These symptoms are directly related to abnormal discharges in the mesial temporal structures, particularly the hippocampus where mossy fiber sprouting is commonly observed. The differential diagnosis includes other focal epilepsies, such as neocortical temporal lobe epilepsy or parietal lobe epilepsy, which may have different aura characteristics. Advanced imaging (MRI, PET) coupled with EEG monitoring is used to precisely localize the seizure focus. Histopathologic confirmation post-surgically may reveal mossy fiber sprouting in cases of hippocampal sclerosis. First-line management involves antiepileptic drugs (AEDs) such as levetiracetam, lamotrigine, or carbamazepine. In patients with drug-resistant mesial temporal lobe epilepsy, surgical resection (e.g., anterior temporal lobectomy) may be indicated. In pregnant women, monotherapy with AEDs like lamotrigine or levetiracetam is preferred due to their safer profiles, and dose adjustments may be necessary because of altered pharmacokinetics during pregnancy. Breastfeeding considerations include monitoring infant exposure while maintaining maternal seizure control. Option A (Activation dentate nuclear) is misleading as it confuses the dentate gyrus with the dentate nucleus of the cerebellum. Option B (Schaffer collateral from c3 to c1) incorrectly identifies the pathway; while the Schaffer collaterals (CA3 to CA1) are important, they are not typically implicated in the epileptogenic reorganization responsible for these auras. Option C (mossy fiber sprouting) is correct, as it reflects the key pathological mechanism in mesial temporal lobe epilepsy that leads to recurrent excitatory circuits and the generation of seizures. \u2022 An epigastric aura with d\u00e9j\u00e0 vu is highly suggestive of mesial temporal lobe epilepsy. \u2022 Mossy fiber sprouting in the hippocampus is a pathological hallmark that may underlie seizure propagation. \u2022 Precise localization of the epileptogenic zone is critical for both medical management and potential surgical intervention. Recent research reinforces the role of mossy fiber sprouting in the pathogenesis of mesial temporal lobe epilepsy. Experimental models continue to explore how this aberrant circuit formation contributes to hyperexcitability, and there is ongoing investigation into targeted therapies that may interrupt this process, providing hope for improved management of refractory cases.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with abdominal rising sensation, deja vu, localization pathophysiology.",
    "option_a": "Frontal",
    "option_b": "Frontotemporal",
    "option_c": "Mesial Temporal",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "The patient\u2019s symptoms of an abdominal rising sensation and d\u00e9j\u00e0 vu are classic for auras seen in mesial temporal lobe epilepsy, which involves the hippocampus and adjacent structures. Localization of epileptogenic activity is aided by recognizing these specific aura types. In mesial temporal lobe epilepsy, pathological processes such as hippocampal sclerosis\u2014often accompanied by mossy fiber sprouting\u2014lead to focally increased excitability. This aberrant electrical activity in the hippocampus precipitates the sensory and experiential aura described. The mesial temporal region, especially the hippocampus, is integral in memory and emotional processing. Seizures arising in this area can produce d\u00e9j\u00e0 vu or experiential phenomena along with autonomic symptoms such as the epigastric rising sensation. Such a clinical picture is typical in patients with mesial temporal lobe epilepsy. Differential diagnoses include extra-temporal epilepsies (e.g., frontal lobe or parietal lobe seizures) which have different clinical semiologies. Mesial temporal lobe epilepsy is best confirmed with a combination of detailed history, scalp or intracranial EEG recordings, and imaging techniques (MRI may reveal mesial temporal sclerosis and PET may show hypometabolism). The first-line treatment for mesial temporal lobe epilepsy involves antiepileptic drugs (AEDs) such as levetiracetam, lamotrigine, or carbamazepine. In refractory cases, surgical intervention (e.g., anterior temporal lobectomy) is considered. In pregnancy, careful selection of AEDs with low teratogenic potential (such as lamotrigine or levetiracetam) is crucial along with close monitoring of serum levels due to pharmacokinetic changes. Patients who are lactating should be counseled regarding medication transfer into breast milk and monitored appropriately. Option C (Mesial Temporal) is correct because it accurately reflects the localization of the epileptogenic focus producing the described auras. Option A (Frontal) and Option B (Frontotemporal) are less likely as they typically produce different semiologies that do not classically include d\u00e9j\u00e0 vu or an epigastric rising sensation. \u2022 Abdominal rising sensations with d\u00e9j\u00e0 vu are highly suggestive of mesial temporal lobe epilepsy. \u2022 Hippocampal involvement (often evident as mesial temporal sclerosis) underpins these clinical manifestations. \u2022 Early and accurate localization is vital for planning effective management, including consideration of surgical options in refractory cases. Recent studies and guidelines underscore the importance of early surgical evaluation in drug-resistant mesial temporal lobe epilepsy. Advances in neuroimaging have improved the accuracy of localization, thereby enhancing surgical outcomes. Updated practice guidelines also emphasize tailored AED management during pregnancy to minimize fetal risk while controlling maternal seizures.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly 50 yrs came with seizure he has hx of recurrent ER vist due to vague abdominal pain what lab to request.",
    "option_a": "Porphyria",
    "option_b": "Paraproteinemia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question describes a patient with seizures who has a history of recurrent, vague abdominal pain. This constellation of symptoms is classically associated with acute intermittent porphyria (AIP), a metabolic disorder of heme synthesis that can present with neurovisceral symptoms. AIP is caused by a deficiency of the enzyme porphobilinogen deaminase. This deficiency results in the accumulation of porphyrin precursors (notably porphobilinogen and delta-aminolevulinic acid) that are neurotoxic. Triggers such as certain drugs, stress, fasting, or hormones can precipitate an acute attack characterized by abdominal pain, neurological disturbances (including seizures), and psychiatric symptoms. Patients with AIP often present with recurrent, poorly localized abdominal pain along with a range of neurological manifestations including seizures. The neurotoxic effects of the accumulated porphyrin precursors can lead to encephalopathy, peripheral neuropathies, and psychiatric symptoms. The diagnosis is confirmed by laboratory testing\u2014especially a urine test for porphobilinogen (PBG) during an acute attack. Differential diagnoses include acute surgical abdomen (e.g., appendicitis), lead poisoning, and other metabolic causes of abdominal pain and neurological symptoms. The management of an acute porphyric attack includes: first-line treatment with intravenous hemin to reduce the synthesis of porphyrin precursors, high-carbohydrate intake (often as IV glucose) to interrupt the porphyrin synthesis pathway, and avoidance of triggering substances. In pregnant patients, hemin and high-carbohydrate therapy are used with careful monitoring, and supportive care is key to reduce maternal and fetal risks. Option A (Porphyria) is correct because it directly points to the disorder that explains the combination of recurrent abdominal pain and seizures. Option B (Paraproteinemia) is incorrect because paraproteinemias are typically associated with plasma cell dyscrasias and conditions like multiple myeloma, which do not commonly present with recurrent abdominal pain and seizures. 1. Recurrent, unexplained abdominal pain with neurological manifestations should prompt consideration of acute intermittent porphyria. 2. The normal physical exam during abdominal pain episodes is a clue, and urinary PBG testing is essential during an acute attack. Recent guidelines continue to endorse the measurement of urinary porphobilinogen in the evaluation of suspected AIP. Advances in genetic testing and enzyme assays also help to establish the diagnosis more definitively, allowing for prompt, targeted therapy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with confusion, recurrent seizure 2 days after hemodialysis, image normal, reason.",
    "option_a": "Water influx inside cell case edema",
    "option_b": "Uremic toxicity",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This patient presents with confusion and recurrent seizures following hemodialysis. The clinical scenario is most consistent with dialysis disequilibrium syndrome (DDS), a well-recognized complication due to rapid osmotic shifts during dialysis. During hemodialysis, rapid removal of urea from the blood leads to a lower plasma osmolality compared to the brain, where urea is cleared more slowly. This creates an osmotic gradient that causes water to move into brain cells, resulting in cerebral edema. DDS can present with symptoms ranging from headache and nausea to confusion and seizures. The temporal relationship (typically during or shortly after dialysis sessions) and the absence of abnormalities on neuroimaging (since the edema is diffuse and not focal) support this diagnosis. Diagnosis is primarily clinical. Differential diagnoses include uremic encephalopathy (usually present prior to dialysis), electrolyte disturbances (such as rapid shifts in sodium or glucose), and stroke. Normal imaging studies help to rule out structural abnormalities. Prevention is key in managing DDS. Guidelines recommend slower rates of urea removal (using shorter or more gradual dialysis sessions) and possibly adjusting the composition of the dialysate to minimize osmolar shifts. In severe cases, supportive measures such as hyperosmolar therapy may be used. In pregnancy or lactation, careful hemodynamic and fluid management is critical to protect both the mother and the fetus, with an emphasis on gradual correction of metabolic derangements. Option A (Water influx inside cells causing edema) is correct because it accurately describes the osmotic mechanism leading to cerebral edema in DDS. Option B (Uremic toxicity) is incorrect because, following dialysis, uremic toxins are usually removed effectively. 1. Always consider dialysis disequilibrium syndrome when new neurological symptoms occur in close temporal relation to hemodialysis, even if imaging is unremarkable. 2. Prevention by gradual correction of uremia is the cornerstone of management. Recent studies and updated dialysis protocols emphasize the importance of adjusting dialysis parameters to mitigate DDS risk. Current recommendations favor gradual urea removal, especially in high-risk patients, to prevent osmotic shifts leading to cerebral edema.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "7 YO boy came with Visual hallucination in term of colorful and circular objects moving from right to left lasted for seconds to minutes, sometimes followed by headache, EEG showed occipital lobe spike what is the management.",
    "option_a": "Carbamezapine",
    "option_b": "Amitriptyline",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The 7-year-old boy\u2019s presentation with brief visual hallucinations described as colorful, circular objects moving across his field of vision, coupled with an occipital spike on the EEG, is indicative of occipital lobe epilepsy. Occipital lobe epilepsy involves abnormal, hyperexcitable neuronal discharges originating in the occipital cortex, which is responsible for processing visual information. These discharges give rise to visual auras that are typically brief and may be accompanied by postictal headaches. Clinically, occipital seizures manifest with simple visual phenomena such as flashing lights or geometric shapes, often lasting seconds to minutes. The EEG finding of occipital spikes further supports the diagnosis and distinguishes it from other causes of visual disturbances such as migraine aura. Diagnosis is established by clinical history and confirmed by EEG. Differential diagnoses include migraine with aura (which usually lasts longer and is not associated with epileptiform discharges on EEG) and non-epileptic visual phenomena. Neuroimaging may be used to exclude structural lesions. First-line management for focal epilepsies like occipital lobe epilepsy in children typically involves the use of carbamazepine, which is effective in controlling focal seizures. Alternatives include lamotrigine or levetiracetam, but carbamazepine has a long track record of efficacy and safety in pediatric patients. In children, long-term therapy requires dose adjustments and careful monitoring for side effects. Though pregnancy isn\u2019t an issue in a 7-year-old, in female patients of child-bearing age, carbamazepine is associated with teratogenic risks; folate supplementation and risk-benefit analyses are warranted in those cases. Option A (Carbamazepine) is correct because it is a well-established first-line anti-seizure medication for focal epilepsies, including occipital lobe epilepsy. Option B (Amitriptyline) is inappropriate because it is primarily used for migraine prophylaxis or depression and does not address the epileptic focus indicated by the EEG. 1. Visual auras in children that are brief and stereotyped should raise suspicion for occipital lobe epilepsy. 2. EEG localization of spikes to the occipital region confirms the diagnosis and guides targeted therapy. Contemporary pediatric epilepsy guidelines continue to support the use of carbamazepine as a first-line treatment for focal seizures. Ongoing research is evaluating newer agents, but carbamazepine remains a cornerstone in the management of occipital lobe epilepsy.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "pregnant lady on low dose of levetiracetam she is sleeping well and good compliance, still having seizure, what do you want to add?",
    "option_a": "Lamictal",
    "option_b": "valproic acid",
    "option_c": "Topamax",
    "option_d": "Phenytoin",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In pregnant women with epilepsy, optimizing seizure control while minimizing fetal exposure to teratogenic medications is essential. This case involves a pregnant woman on a low dose of levetiracetam who continues to experience seizures, indicating that her current regimen may be insufficient. Pregnancy induces pharmacokinetic changes such as increased volume of distribution and enhanced drug clearance, which can lower the plasma levels of antiepileptic drugs like levetiracetam. Inadequate seizure control can result from subtherapeutic dosing, necessitating adjunctive therapy to reduce maternal and fetal risks. Persistent seizures during pregnancy not only jeopardize maternal health but can also lead to adverse fetal outcomes, such as miscarriage, preterm labor, or developmental issues. Therefore, effective adjunctive therapy is critical when monotherapy fails to control seizures. The therapeutic decision is based on clinical observation of ongoing seizures despite good compliance with levetiracetam. Therapeutic drug level monitoring and evaluating pharmacokinetic changes in pregnancy are part of the management strategy. Differential considerations include non-adherence (ruled out here) and dose insufficiency. First-line management in pregnant patients emphasizes monotherapy at the lowest effective dose; however, when monotherapy is inadequate, adjunctive therapy is indicated. Lamotrigine (Option A) is frequently added because it has a favorable safety profile in pregnancy, with a lower risk of congenital malformations compared to drugs like valproic acid (Option B), topiramate (Option C), or phenytoin (Option D). In practice, adding lamotrigine is done with careful monitoring of serum levels and dose adjustments as pregnancy progresses. Additionally, folate supplementation is critical with lamotrigine to further reduce the risk of neural tube defects. Option A (Lamictal/Lamotrigine) is correct given its efficacy as an adjunctive agent and its well-documented safety profile during pregnancy. Option B (Valproic Acid) is contraindicated due to its high teratogenic potential. Option C (Topamax) is associated with risks such as cleft lip/palate and cognitive effects. Option D (Phenytoin) carries risks for fetal hydantoin syndrome and other teratogenic effects. 1. In pregnant patients with epilepsy, if seizure control is suboptimal, consider either increasing the dose or adding a second agent that is known to be safe in pregnancy. 2. Lamotrigine remains one of the most preferred adjunctive drugs due to its lower teratogenic risk and favorable side effect profile. Recent guidelines from epilepsy and obstetric societies continue to endorse the use of lamotrigine as an effective, low-risk adjunct in pregnant patients failing monotherapy. Ongoing research focuses on optimizing dosing strategies during pregnancy due to altered pharmacokinetics.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Vague scenario going with CIDP of old female with neuropathy and paraproteinemia. WHAT IS THE RX:",
    "option_a": "Monthly IVIg",
    "option_b": "Dr Muteb monthly IVIG",
    "option_c": "Periodic Plex ?",
    "option_d": "Afaf read >",
    "option_e": "Prednisolone",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune\u2010mediated disorder of the peripheral nerves characterized by progressive weakness and sensory dysfunction. Its management hinges on immunomodulatory therapies that reduce inflammation, promote remyelination, and improve function. CIDP involves an autoimmune attack against myelin in the peripheral nerves. In some older patients, CIDP may be associated with paraproteinemia, where monoclonal proteins are present. Although in some cases this may signal an anti\u2010myelin associated glycoprotein (MAG) neuropathy variant, the clinical scenario described fits a typical CIDP pattern where immunomodulation (especially IVIg) can alter the disease course. Patients typically present with a slowly progressive, symmetric weakness and sensory loss in the limbs. Deep tendon reflexes are often reduced or absent. Electrophysiological testing reveals demyelinating features, and cerebrospinal fluid analysis may show an elevated protein level without pleocytosis. Diagnosis is based on clinical evaluation supported by nerve conduction studies and CSF analysis. Differential diagnoses include Guillain\u2013Barr\u00e9 syndrome (acute counterpart), diabetic neuropathy, and paraproteinemic neuropathies such as anti-MAG neuropathy. Serial nerve conduction studies can help differentiate CIDP from these conditions. First\u2010line treatment includes immunomodulatory therapy. Intravenous immunoglobulin (IVIg) administered in monthly cycles is one of the main treatments and is particularly useful in patients who may be at risk for corticosteroid complications. Plasma exchange and corticosteroids are alternative first\u2010line therapies. In pregnancy and lactation, IVIg is generally considered safe and is often preferred over corticosteroids due to a more favorable side\u2010effect profile. Option A (Monthly IVIg) is the standard treatment for CIDP and is supported by current guidelines. Option B is an unclear variant of IVIg therapy with unnecessary naming. Option C (Periodic Plex) and Option D (Afaf read >) do not represent valid treatment modalities. Option E (Prednisolone) is an acceptable alternative, but given the patient factors (older female, possible risks of steroid side effects), IVIg is favored. \u2022 CIDP typically presents with progressive motor and sensory deficits along with diminished reflexes.  \u2022 IVIg is a first\u2010line, well\u2010tolerated therapy for many CIDP patients, especially in the elderly.  \u2022 Paraproteinemia in CIDP warrants further evaluation to exclude anti\u2010MAG neuropathy. Recent randomized controlled trials and consensus guidelines continue to support IVIg as a first\u2010line treatment for CIDP. Its efficacy and safety profile, particularly in older patients and during pregnancy/lactation, have been reaffirmed in updated clinical guidelines.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "a patient with seizure semiology that suggest MSTLE with epigastric sensation and also hearing hallucination (However the diagnosis is not mentioned and very confusion gave picture of both type (medial and lateral temporal epilepsy) what is the responsible gene:",
    "option_a": "LG1 gene",
    "option_b": "others gene I don\u2019t remember",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Temporal lobe epilepsy can be subdivided into mesial and lateral types based on the anatomical location and seizure semiology. Familial forms, particularly those featuring auditory auras, are most commonly linked to mutations in the LGI1 gene. The LGI1 (leucine\u2010rich glioma inactivated 1) gene plays a key role in synaptic transmission and neuronal excitability within the temporal lobe. Mutations in LGI1 disrupt these functions, predisposing individuals to focal seizures, especially in families with autosomal dominant lateral temporal lobe epilepsy. Patients with lateral temporal lobe epilepsy often exhibit auditory hallucinations, while mesial temporal involvement may be indicated by epigastric sensations. In cases where features overlap, a mutation in LGI1 should be highly suspected, as it is most typically associated with auditory auras in familial seizures. Diagnosis is primarily clinical, supported by EEG and brain imaging (MRI). Genetic testing can confirm LGI1 mutations in familial cases. Differential diagnoses include other forms of temporal lobe epilepsy without a clear genetic basis, as well as extratemporal epilepsies. The treatment of familial temporal lobe epilepsy generally follows standard antiepileptic drug (AED) protocols. Drugs such as carbamazepine or oxcarbazepine are commonly used. Special consideration is given during pregnancy and lactation, with agents like lamotrigine and levetiracetam frequently preferred due to their safety profiles. Option A (LGI1 gene) is the recognized genetic association in familial lateral temporal lobe epilepsy and is the best answer. Option B (others gene I don\u2019t remember) lacks specificity, and Options C and D are not provided, making Option A the clear choice. \u2022 LGI1 mutations are strongly linked to familial lateral temporal lobe epilepsy characterized by auditory hallucinations.  \u2022 Overlap in auras (epigastric and auditory) may indicate involvement of both mesial and lateral structures, with LGI1 remaining the prime candidate in familial cases. Recent genetic studies and revised epilepsy classifications continue to underscore the significance of LGI1 mutations. The precise mechanisms are an area of ongoing research, but current evidence supports the use of genetic testing in familial epilepsy syndromes.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "scenario of old pt. With comorbidity renal stone, heart failure and Atrial fibrillation and post stroke seizure best AED:",
    "option_a": "Lamictal",
    "option_b": "phenytoin",
    "option_c": "Topamax",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Post\u2010stroke seizures in the elderly represent a common form of acquired epilepsy. The selection of an antiepileptic drug (AED) in this population must account for comorbid conditions and polypharmacy to reduce side effects and drug interactions. Cerebral infarction can lead to the formation of epileptogenic foci due to gliosis and altered neuronal networks. The post\u2010ischemic brain is particularly vulnerable, and seizures may arise as a delayed complication. AEDs are chosen not only for efficacy but also for safety, given the patient\u2019s comorbidities (renal stones, heart failure, and atrial fibrillation). Post\u2010stroke patients often present with focal onset seizures. In the elderly, it is essential to choose an AED with minimal adverse effects on cardiac function and renal profiles. Lamotrigine is known for its favorable adverse effect and drug\u2010interaction profile in this setting. Diagnosis is based on clinical history, EEG monitoring, and brain imaging to exclude other causes of seizure activity, such as metabolic disturbances or additional cerebrovascular events. Differential diagnoses include other secondary epilepsies caused by brain tumors or metabolic derangements. Lamotrigine (Lamictal) is preferred in elderly patients due to its overall tolerability, relatively benign cardiac profile, and minimal drug interactions. It is dosed carefully with slow titration to mitigate the risk of rash. In pregnancy and lactation, lamotrigine is one of the AEDs with a comparatively favorable safety profile, though plasma levels may need monitoring due to changes in metabolism. Option A (Lamictal) is the correct answer given its efficacy and safety in the elderly, particularly in patients with multiple comorbidities. Option B (Phenytoin) has a narrow therapeutic index and more potential for drug interactions, while Option C (Topamax) is associated with an increased risk of kidney stones, making them less suitable choices in this clinical scenario. \u2022 Post\u2010stroke seizures are most often focal, and lamotrigine\u2019s favorable side\u2010effect profile makes it a preferred agent in the elderly.  \u2022 Topiramate is contraindicated in patients with a history of renal stones due to its propensity to promote kidney stone formation. Recent guidelines and expert opinions favor the use of lamotrigine as a first\u2010line agent for focal seizures in the elderly, particularly when multi\u2010comorbidity and polypharmacy are present. Studies continue to support its efficacy and safety profile in this patient group.",
    "exam_year": "2020",
    "exam_type": "Part II"
  }
]